Seven novel modulators of the analgesic target NaV 1.7 uncovered using a high-throughput venom-based discovery approach.
Klint, J.K., Smith, J.J., Vetter, I., Rupasinghe, D.B., Er, S.Y., Senff, S., Herzig, V., Mobli, M., Lewis, R.J., Bosmans, F., King, G.F.(2015) Br J Pharmacol 172: 2445-2458
- PubMed: 25754331 
- DOI: https://doi.org/10.1111/bph.13081
- Primary Citation of Related Structures:  
2MPQ - PubMed Abstract: 
Chronic pain is a serious worldwide health issue, with current analgesics having limited efficacy and dose-limiting side effects. Humans with loss-of-function mutations in the voltage-gated sodium channel NaV 1.7 (hNaV 1.7) are indifferent to pain, making hNaV 1.7 a promising target for analgesic development. Since spider venoms are replete with NaV channel modulators, we examined their potential as a source of hNaV 1.7 inhibitors.
Organizational Affiliation: 
Centre for Pain Research, Institute for Molecular Bioscience, St. Lucia, Qld, Australia.